Podcasts about medidata

Send us a textAI promises to revolutionize clinical trials and reshape regulatory oversight. But is the pharma industry ready? And can the FDA keep pace with the technology? In this episode of the HealthBiz Podcast, host David Williams is joined by Tom Doyle, Chief Technology Officer of Medidata, to discuss the promises and potential pitfalls of AI in clinical trials.

When Josh Schwartz arrived at Medidata, the life sciences innovation company was entering unfamiliar waters. Having just gone public, Medidata was shifting from a fast-growing startup to a more structured, scalable organization. For Schwartz, who initially led revenue recognition, this was the beginning of both a personal and professional evolution that would mirror the company's own transformation. “It was a point in time where we were starting to bring in specialization, starting to think about really scaling up our business and thinking about the future,” he recalls.As Medidata scaled, so did Schwartz's responsibilities. His stubborn curiosity led him to explore beyond his initial role, uncovering inefficiencies and taking on more of the finance function. “I just started asking questions and driving people crazy,” he says, noting that his eagerness to improve processes soon expanded his role across finance. This growth trajectory from accounting to eventually becoming CFO in 2022 parallels the evolution of Medidata's financial operations.Similarly, the metrics that once guided Medidata's growth had to evolve as well. Early on, Josh explains, “We were focused on how many products our customers were using.” But as Medidata transformed into a platform-based organization, the metrics shifted. “It's no longer about products; it's about how much data we are driving through the platform.”This alignment between Josh's career journey and the company's evolving metrics highlights the adaptive approach both have taken to fuel Medidata's latest growth chapter. Today, Josh leads a finance team that embodies the same forward-thinking approach he embraced early in his career, constantly rethinking metrics to drive growth.

Input from research sites is essential for developing clinical technologies that are practical, efficient, user-friendly, and aligned with the real-world needs and challenges of trials. Understanding this need, Medidata Solutions hosted an interactive Site Tech Board through SCRS to learn how to improve their technology and processes directly from sites. Tune in as Robin Douglas, Vice President of Research Site Engagement at Medidata, highlights how the organization is creating a better experience for sites and patients through this feedback.

2024-07-19 Hosts Jane Myles and Angela Radcliffe were joined by Alicia C. Staley from Medidata Solutions for a fabulous conversation about her whitepaper on Medidata's Patient Centricity by Design (PCbD) process and the work they are doing to accommodate the perspectives and preferences of patients and caregivers.You can join TGIF-DTRA Sessions live on LinkedIn Live Audio on Friday's at 12:00 PM ET by checking out our LinkedIn. Follow the Decentralized Trials & Research Alliance (DTRA) on LinkedIn and X. Learn more about Membership options and our work at www.dtra.org.

ACRO's Good Clinical Podcast is back! This week, Stacy Hurt, Chief Patient Officer at Parexel, and Alicia Staley, Vice President, Patient Engagement at Medidata joined the podcast to discuss how we can turn patient centricity from “buzz words” to action. They discuss how their own experiences as patients have informed their approach to clinical research and the important role that an upstream patient voice plays in reducing the burden on patients.

2024-06-14 Hosts Dr. Amir Kalali and Jane Myles were joined by Anthony Costello (Medidata) for a conversation around data diversity, data access, and rights, and his experience at Medidata, as well as industry wide.You can join TGIF-DTRA Sessions live on LinkedIn Live Audio on Friday's at 12:00 PM ET by checking out our LinkedIn. Follow the Decentralized Trials & Research Alliance (DTRA) on LinkedIn and X. Learn more about Membership options and our work at www.dtra.org.

Lors de cette séance, l'indice parisien n'a cessé de plonger depuis l'ouverture, cédant près de 150 points en fin de journée. Finalement le CAC 40 s'est légèrement repris, clôturant la journée sur une baisse de 0,93% à 8 016 points, avec des volumes d'échanges de 4 milliards d'euros sur la journée. Cette baisse s'inscrit dans un contexte marqué par la publication de résultats trimestriels contrastés, ainsi que par de nouvelles statistiques américaines indiquant un ralentissement de la première économie mondiale au premier trimestre. En effet, la croissance économique des États-Unis a été bien inférieure aux attentes entre janvier et mars, avec un PIB en hausse de seulement 1,6% en rythme annualisé, alors que les prévisions tablaient sur une progression de 2,5%, après une hausse de 3,4% au cours des trois derniers mois de 2023.Parmi les valeurs en hausse sur le CAC 40, Sanofi s'octroie 4,47% grâce à des résultats trimestriels supérieurs aux attentes des analystes. Au cours des trois premiers mois de l'année, le chiffre d'affaires du groupe pharmaceutique a augmenté de 2,4%, atteignant 10,46 milliards d'euros.Dans son sillage on retrouve Eurofins Scientific en hausse de 1,16%, puis STMicroelectronics qui se reprend après avoir initialement perdu 5% environ à l'ouverture. Le fabricant franco-italien de composants électroniques a vu son bénéfice net diminuer de moitié au premier trimestre, et le groupe a revu à la baisse ses prévisions annuelles en termes de revenus et de marge.En revanche, Dassault Systèmes se classe en bas de tableau avec une baisse de 4,24%. Bien que les résultats soient honorables, ils sont quelque peu entachés par la performance de sa filiale spécialisée dans le suivi des essais cliniques, Medidata, dont les revenus ont baissé de 3%.Juste derrière, LVMH cède 2,77%, Hermès perd 2,38%, le groupe a annoncé une augmentation de 12,6% de son chiffre d'affaires au premier trimestre par rapport à l'année précédente, principalement stimulée par ses ventes dans le secteur de la maroquinerie. Cependant, les performances mitigées dans les catégories des montres et des parfums ont pénalisé le groupe. Sur le SBF 120, Verallia et Eramet enregistrent une hausse de plus de 4%. En revanche X-Fab Silicon chute de 6,83% après avoir annoncé des prévisions prudentes pour son deuxième trimestre. Puis juste derrière, Worldline lâche 6,42%.Et enfin pour terminer, à la clôture à Paris, les indices américains suivent la même tendance, avec le Dow Jones et le Nasdaq en baisse d'environ 1,70% chacun. Une autre actualité à Wall Street concerne l'action de Meta, la maison-mère de Facebook et Instagram, qui plonge de 13% pour le moment. Les prévisions de ventes trimestrielles inférieures aux attentes et l'accélération des investissements dans l'intelligence artificielle et le metaverse suscitent des inquiétudes pour les investisseurs.Antoine MORISSE (redaction@boursorama.fr)

Learn how dynamic benchmarks are shaping the future of clinical trial finances, offering adaptability, transparency, and stronger relationships between sponsors, CROs, and research sites. Shelley Douros, the Senior Director of Clinical Trial Financial Management, and Tina Mincher, the Director of Client Strategy at Medidata share their revolutionary CAP approach (Committed, Anticipated, and Projected) that is transforming how budgets are approached. Tune in to learn how to ensure fair market value and foster better collaboration with clinical research site partners.

Roman Bartoš odišiel do USA pred viac ako desiatimi rokmi. Začínal ako finančník v IBM, neskôr sa presunul do firmy Medidata. Ako skončil v Amerike, akí sú podľa neho Američania, prečo miluje vôňu oceánu a kedy doma otvárajú vianočné darčeky? V podcast Sme svetoví odpovedá na tieto aj iné otázky. Podcast vznikol vďaka finančnej podpore Ministerstva zahraničných vecí a európskych záležitostí SR. Námet na projekt vytvorila Kristína Sojáková, ktorá pracuje pre IBM v New Yorku a spoluvedie skupinu Slovak Professionals in New York. – Ak máte pre nás spätnú väzbu, odkaz alebo nápad, napíšte nám na⁠ podcasty@sme.sk⁠ – Všetky podcasty denníka SME nájdete na⁠ sme.sk/podcasty⁠ – Podporte vznik podcastov denníka SME a kúpte si digitálne predplatné⁠ SME.sk⁠ na⁠ sme.sk/podcast⁠ – Ďakujeme, že počúvate⁠ podcasty denníka SME⁠.

Billy Martin is a Senior Director for Strategic Programs and Leadership Development at Medidata Solutions as well as the creator of FLIP'D Coaching for Performance. The FLIP'D framework has been experienced by over 4000 corporate leaders around the world since it's inception. Billy spent 10 years at Salesforce.com before coming to Medidata.  He has a Masters Degree in Sports Medicine and an MBA degree in Technology Management. Billy co-founded several technology companies on his journey toward leadership development. Billy has six Amazon.com Top Sellers on Sports Officiating and Business he loves teaching other aspiring referees / umpires — and does so for high school soccer and basketball, as well as collegiate softball.  Tony Severino is a business leader, leadership skill developer, master facilitator and coach. He draws on the experience as a business leader and coach who led organizations at companies like Xerox, Salesforce and his own company. He spent his time at Salesforce as director of sales leader enablement and program manager where Tony's team created and delivered the highest ranked, and award winning global leadership programs in the company's history. Tony has personally facilitated leader training for thousands of leaders at Salesforce. Now at FLIP'D, Tony and Billy work with companies to develop their leaders at all levels within the organization using proven, engaging workshop content and coaching tools. To learn more about Billy, you can go to his Linkedin profile: @crmbilly To learn more about Tony, you can go to his Linkedin profile: @arsevr or You can go to their website: flipdcoaching.com --- Support this podcast: https://podcasters.spotify.com/pod/show/lyndsay-dowd/support

Alicia Staley is the VP of Patient Engagement at Medidata and working to bring more technology and software solutions to clinical research. With a focus on creating patient-centric clinical trials, Alicia emphasizes the value of digital tools to drive diversity of participation and retention. As a cancer survivor and patient advocate, Alicia has deep insights into how clinical trials are run and who participates.  Alicia explains, "I think the entire industry is still responding to what life looks like post-COVID. However, in particular, in clinical research, this gravitation toward more digital tools to support clinical research is still very much at the forefront. Topics like decentralized clinical trials and patient portals, patient registries, and ways to support the patient through the clinical journey using digital tools, sensors, and wearables are very much at the forefront of the conversations we're having today. Clearly there is an interest in going in that direction. And I think we learned during the pandemic that these tools are great resources for expanding the potential participation in clinical research to essentially a broader audience of participants." "It took the pandemic for the industry to realize that these tools are valuable resources. I think there had been historically quite a bit of hesitancy to embrace technical solutions like eConsent, eCOA, ePRO, or any of the eSource tools. And I think the pandemic made us realize that these tools are here, they're here to stay, and they work very, very well. But our hand was never forced in the way it was during the pandemic." #Medidata #DecentralizedTrials #Diversity #ClinicalTrials #LifeSciences #PatientExperience Medidata.com Download the transcript here

Alicia Staley is the VP of Patient Engagement at Medidata and working to bring more technology and software solutions to clinical research. With a focus on creating patient-centric clinical trials, Alicia emphasizes the value of digital tools to drive diversity of participation and retention. As a cancer survivor and patient advocate, Alicia has deep insights into how clinical trials are run and who participates.  Alicia explains, "I think the entire industry is still responding to what life looks like post-COVID. However, in particular, in clinical research, this gravitation toward more digital tools to support clinical research is still very much at the forefront. Topics like decentralized clinical trials and patient portals, patient registries, and ways to support the patient through the clinical journey using digital tools, sensors, and wearables are very much at the forefront of the conversations we're having today. Clearly there is an interest in going in that direction. And I think we learned during the pandemic that these tools are great resources for expanding the potential participation in clinical research to essentially a broader audience of participants." "It took the pandemic for the industry to realize that these tools are valuable resources. I think there had been historically quite a bit of hesitancy to embrace technical solutions like eConsent, eCOA, ePRO, or any of the eSource tools. And I think the pandemic made us realize that these tools are here, they're here to stay, and they work very, very well. But our hand was never forced in the way it was during the pandemic." #Medidata #DecentralizedTrials #Diversity #ClinicalTrials #LifeSciences #PatientExperience Medidata.com Listen to the podcast here

In this episode, host Shikha Jain, MD, speaks with Medidata's Alicia Staley about enhancing the patient care experience from a former patient's perspective, building empathetic technical solutions and more. •    Welcome to another exciting episode of Oncology Overdrive 1:11 •    About Staley 1:22 •    The interview 2:37 •    Tell me about your journey and how you ended up at Medidata with your unique skillset? 2:55 •    Jain and Staley on medical advances in cancer care, and how delivery of that care has not changed 10:36 •    Jain and Staley on the evolution of healthcare as a business and its affects on the doctor-patient relationship 13:27 •    What is Medidata and how you end up doing the work you do as VP there? 15:48  •    How do you translate and communicate emotion into the bottom line in the space that you are in, and how these changes will help others reach their goals? 20:05 •    As a former patient, what are your thoughts on how we can improve clinical trial design?  26:19  •    Staley on the importance of finding examples of organizations that have successfully navigated the important conversations surrounding health care 30:29  •    If you could create your utopia of a health care system, what do you envision it would look like? 31:19 •    If someone could only listen to the last few minutes of this episode, what would you want them to take away? 34:15 •    How to contact Staley 35:28 •    Thanks for listening 36:21 Alicia Staley has over 20 years of experience in software design and information systems management and is a three-time cancer survivor. At Medidata, Alicia works to infuse the patient perspective throughout the product development lifecycle and help engage patients in novel ways. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on Twitter and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on Twitter: @ShikhaJainMD. Staley can be reached via LinkedIn, or on Twitter @stales.   Disclosures:  Jain reports no relevant financial disclosures. Staley is a full-time employee at Medidata.

4:26  Labiotech news6:36  Medidata21:43 Bill & Melinda Gates Research InstituteThis week's podcast is sponsored by Jubilant Biosys.May 20 is International Clinical Trials Day.ECRIN,  the European Clinical Research Infrastructure Network, is a not-for-profit organization that supports the conduct of multinational clinical trials in Europe. Based in Paris, France, the organization launched International Clinical Trials Day (ICTD) in 2005 to commemorate the day when James Lind started his clinical trial on scurvy in 1747, on May 20.ECRIN is hosting an event, both in-person and online, on Monday, May 23, called Decentralised Clinical Trials: challenges and opportunities. While the physical event in Warsaw, Poland, is full, online registration can be found here.International Clinical Trials Day is also supported and promoted by a range of charities, companies and organizations, such as the 13,000-member Association of Clinical Research Professionals (ACRP), which is the only non-profit organization solely dedicated to representing, supporting, and advocating for clinical research professionals.To celebrate the day, we have two interviews about the importance of the event and clinical trials in general. We have conversations with Dr. Michael Dunne, head of development and chief medical officer of the Bill & Melinda Gates Medical Research Institute, and Kelly McKee, vice president, decentralized clinical trials (DCT) and patient registries at Medidata.

Wayne Walker is Senior Vice President, Product for Rave Platform Technology (including Rave EDC, Rave RTSM, Rave Imaging, Rave Coder, and Rave Safety Gateway) at Medidata. His responsibilities include the strategy, development, and delivery of these products across all Research & Development disciplines. Before joining Medidata, Wayne spent 12 years overseeing Product Management for clinical technology used by Data Management and Biometrics at PRA Health Sciences. This involved oversight of Platform as a Service, Software as a Service, on-premise deployed environments, and in-house developed solutions This week we discuss the vendor/site relationships, why there is a proliferation of disparate systems, the potential of direct to EDC data entry and so much more.

Madalina Tanasie joins us to share her unique leadership journey as she transitioned from eng to operations, then back to her current technical role as CTO @ Collibra. We also cover strategies to improve engineering efficiency within your organization, factors to consider when scaling eng teams, maximizing your ROI when it comes to R&D, dispelling concerns when implementing culture changes, frameworks for scaling up, and more.ABOUT MADALINA TANASIEMadalina Tanasie is the Chief Technology Officer and an Executive Committee member at Collibra, where she oversees and leads the Software Engineering, Architecture, Production Engineering, Test Engineering, and Security activities.Madalina has over 18 years of software engineering leadership experience and her expertise is in service-oriented architecture, cloud-native distributed systems, and product operations with a focus on engineering practices, scale, and operational excellence. Prior to joining Collibra in 2020, she was the Engineering VP for Medidata Solutions' Unified Platform Organization, an organization she built from the ground up and led since 2010.She has been recognized as one of the Top 25 Software CTOs of 2023 by The Software Report.Additionally, she is a proud sponsor of Collibra's Women in Technology, and an active member of CHIEF, a network focused on connecting and supporting women executive leaders. Ms. Tanasie earned her BS and Master's in Computer Science at Polytechnics University of Bucharest."The reality is that they need process and structure to eliminate the noise and to create a space for solving really, really deep challenging problems. They actually want the process for the part that is mundane and boring and disruptive. So as they discuss about what's making their life harder than it needs to be, we are coming back to a lack of process, a lack of uniformity, a lack of clear communication channels between themselves or between other departments.”- Madalina Tanasie   Check out QA Wolf!Looking for a way to increase end-to-end test coverage, speed up your release cycles and reduce bugs from shipping to production? QA Wolf will build, run and maintain your test suite - so that you don't have to.QA Wolf gets you to 80% automated end-to-end test coverage in 4 months - and keeps you there – So your team can stay focused on shipping!Learn more & schedule a 30 min demo at qawolf.com/elcLooking for ways to support the show?Send a link to the show to your marketing team! https://sfelc.com/podcastsIf your company is looking to gain exposure to thousands of engineering leaders and key decision-makers, we have sponsorship opportunities available.To explore sponsor opportunities, email us at hello@sfelc.comSHOW NOTES:Madalina's unexpected career journey, beginning @ Medidata (2:13)How Madalina transitioned from engineering into operations @ Collibra (4:57)Qualities that make Collibra's culture stand out (5:46)What opportunities stood out when Madalina was evaluating the Collibra role (7:35)Four considerations to keep in mind when scaling eng teams (9:07)The Spotify model vs. Agile model & what worked for Collibra (15:19)Challenges to adopting new management models (19:18)Strategies for navigating people's expectations (20:58)Insights gained from Madalina's “listening tour” (23:20)Frameworks for addressing concerns around culture while scaling (25:04)Madalina's perspectives on improving engineering efficiency (26:51)The right balance between cost of ownership and R&D (30:07)Collibra's new product introduction process & its impact on R&D (31:28)Questions to help guide teams throughout the new framework (33:11)Rapid fire questions (34:22)This episode wouldn't have been possible without the help of our incredible production team:Patrick Gallagher - Producer & Co-HostJerry Li - Co-HostNoah Olberding - Associate Producer, Audio & Video Editor https://www.linkedin.com/in/noah-olberding/Dan Overheim - Audio Engineer, Dan's also an avid 3D printer - https://www.bnd3d.com/Ellie Coggins Angus - Copywriter, Check out her other work at https://elliecoggins.com/about/

Clinical trials are essential to progress in medicine, but racial and ethnic minorities are frequently underrepresented in such studies. In this ASCO Education podcast episode, we will examine this issue with Dr. Carol Brown, gynecologic cancer surgeon and Chief Health Equity Officer at Memorial Sloan Kettering Cancer Center, Dr. Ana Maria Lopez, Professor and Vice Chair of Medical Oncology at Sidney Kimmel Medical College and former Chair of ASCO's Health Equity Committee and Mr. Ted Bebi, Innovation Manager at Medidata Solutions. They discuss how diversification of clinical trials contributes to health equity (4:03), barriers to participating in clinical trials (14:37), and what clinicians and trial sponsors can do to improve participant diversity in clinical trials (20:25).  Speaker Disclosures Dr. Carol Brown – None Ted Bebi: Employment – Medidata (a Dassault Systèmes company); Stock and Other Ownership Interest – Pfizer, Eli Lily, Abbvie, Merck, BMY        Dr. Ana Lopez - None Resources ASCO-ACCC Initiative to Increase Racial & Ethnic Diversity in Clinical Trials Journal Article: Increasing racial and ethnic diversity in cancer clinical trials Journal Article: Representation of minorities and women in oncology clinical trials Podcast: Impact of Implicit Racial Bias on Oncology Patient Care and Outcomes ASCO-ACCC JustASK Training Program If you liked this episode, please follow the show. To explore other educational content, including courses, visit education.asco.org. Contact us at education@asco.org. TRANSCRIPT Dr. Carol Brown: Welcome to the ASCO Education podcast. I'm Dr. Carol Brown, a gynecologic cancer surgeon and the Chief Health Equity Officer at Memorial Sloan Kettering Cancer Center. Our guests and I will be exploring the problems and solutions with regards to racial disparities in clinical trials.   A necessary element for conducting clinical trials is, obviously, the enrollees or participants. Racial and ethnic diverse groups are frequently underrepresented in clinical trials, despite having a disproportionate burden for certain cancers. In addition, there is increasing evidence that a person's individual genetic makeup may determine the level of toxicity or efficacy of a new cancer drug specifically. Therefore, when we don't have enough diversity in our cancer clinical trials, it can really undermine the generalizability of our results. And so, to address this gap, in its recent updated guidance to industry, the US Food and Drug Administration stated that enrollment in clinical trials should reflect the diversity of the population who ultimately use a treatment.   In 2022, ASCO and the Association of Community Cancer Centers issued a joint statement recommending that anyone designing or conducting trials should complete recurring education, training, and evaluation to demonstrate and maintain cross-cultural competencies, mitigation of bias, effective communication, and a commitment to achieving equity, diversity, and inclusion.   Joining me to discuss this important topic today is Dr. Ana Maria Lopez, who's the Professor and Vice Chair of Medical Oncology at the Sidney Kimmel Medical College. And she's the former Chair of ASCO's Health Equity Committee. Our second guest is Mr. Ted Bebi, Innovation Manager at Medidata Solutions. His research explores underrepresentation of black patients at clinical trials and how diversity impacts clinical trials.  Participant disclosures for this episode are listed on the podcast page.  So why should we care about improving diversity in clinical trials? Dr. Lopez? Dr. Ana Maria Lopez: We are clinicians. We are wanting to take care of our patients as best as possible, and we can only do that if our studies include everyone. An example that I often think about is the concept of airbags began in 1953, and in 2008, the National Highway Traffic Safety Administration came out and said, “You know what? We should be testing airbags on small female crash test dummies because otherwise, we don't know that these airbags will be safe.” And in fact, there were data that the airbags that existed put women and children at a much higher risk for injury or death. So, we want to be ahead of that curve, and we want to allow the best possible treatment. Dr. Carol Brown: So, Mr. Bebi, what would you say about how we could improve diversity in clinical trials? Ted Bebi: So I really like the example of the airbags that Dr. Lopez brought up because it makes it clear when building a product it's important to test the product in a representative sample of the population that will ultimately end up using it. It's the same with products like medications. If you want an efficacious drug, you should test it in the appropriate population. It's what constitutes good science. Additionally, adequate diversity in clinical trials is also important because it's ultimately an issue of health equity and providing fair access. Dr. Carol Brown: Could you kind of go on from there and talk about, specifically, how does diversifying the group of people that participate in clinical trials actually translate into increasing health equity?  Ted Bebi: Well, participating in a clinical trial is a form of receiving health care. Often, we are talking about patients for which a clinical trial might be their last resort. And even if not, participating in a clinical trial means gaining early access to potentially life-changing drugs that could become the new industry standard and doing so at no cost. So, you're receiving care and follow-up from some of the best specialists in the field. So having fair access to this opportunity for all patients is definitely a health equity issue. Dr. Carol Brown: Great. Dr. Lopez, how would you answer that question about how does diversifying clinical trials contribute to health equity? Dr. Ana Maria Lopez: Yeah, no, I think I agree with everything that Mr. Bebi said. In addition, I think we have to remember that diversity is more than race. Race is truly a social construct. We need to think about gender. We need to think about age, the whole lifespan, and people are living longer. How we metabolize medications at different time points in our life may vary. So, lots of different factors that we can consider when we think of diversity. But the gold standard is really: Are folks getting the best outcome possible? And as long as that metric is not being reached, we need to be thinking of how can we facilitate that. Dr. Carol Brown: So, Dr. Lopez, you brought up this concept that health equity is really the best outcome possible. Could you comment a little bit about how do we know, particularly in cancer, what is the best outcome possible? So how do we determine what the reference is for that, so we can figure out whether our patients are actually getting health equity? Dr. Ana Maria Lopez: Sure. So, we use different time points. We can look at relapse rates, survival rates, and of course, part of that may be comorbidities. Certain comorbidities that people have may impact their cancer treatment outcomes. So, it is complex, but it is important for us to take a look contextually at what the patient's risk is and what the patient's outcome would be. Dr. Carol Brown: We can kind of all agree that when we're talking about equity, it's getting the best outcome for everybody, no matter what they're bringing to it. And I really like your comment, Dr. Lopez, about race being not only the only factor but remembering that it is a social construct. If you could add to that, Mr. Bebi. Ted Bebi: We're talking a lot about diversity in clinical trials in terms of race and ethnicity, and that is something that is ultimately very important. But we're talking about diversity in all sorts of aspects. We're talking about diversity with age. We're talking about diversity with sex, with socioeconomic aspects because we often use race as a proxy for other things that might be going on in patients' lives. And we need to consider all of this part of diversity in clinical trials because once the drug is out in the market, it will be an intersection of potentially all of those identities and many things going on in their life that might affect how they respond. So, when we're thinking about race as a diversity point, we might be using it as a proxy for a specific type of individual, a specific patient journey that we want to make sure to include. It's not necessarily that race is the end-all, be-all measure of diversity; it's that we want to capture the true patient experience for that disease. Dr. Ana Maria Lopez: What I think is also really interesting is how we collect the data. And some of what the last couple of years have taught us is that folks may not trust our healthcare systems, and so folks may not be willing to say, ‘I am X, Y, or Z,' which certainly puts us a little bit in the void. So how important it is for us as clinicians, as researchers, to be part of creating an environment where patients can feel that ‘Yes, I can trust and I can share, and I can say, this is who I am,' because that could impact clinical care. Dr. Carol Brown: So, acknowledging that race is a social construct and that it really is used as a surrogate for other social determinants of health and other factors that affect health, and again, really acknowledging what you said, Dr. Lopez, that even asking people to identify their race is extremely problematic. But given what we do know and what our experience has been in the clinical trial world, first, Mr. Bebi, could you comment about what has been your experience and your research with the current state of participation by diverse racial and ethnic groups in clinical trials in the United States? What have you found in your research?  Ted Bebi: Recently, at Metidata, we published a paper where we looked at the state of black participation in clinical trials. We found the level at which you look at the data really matters. For example, when we looked at racial diversity across all US trials, black representation actually matched the proportion of black people represented in the 2020 US National Census, which is about 14%. But looking deeper, there were actually huge differences by therapeutic and disease area. And specifically, we saw that in oncology, black participation was only at around 8.5%, so far below the representation of black people in the United States.   Another interesting story is that when we were looking at the central nervous system therapeutic area, overall, we saw a pretty high rate of black participation at around 20%. But when we looked at one of the largest central nervous system indications, Alzheimer's, we saw only 5% black participation, so much, much lower. What we discovered is that within this therapeutic area, there were actually a lot of psychiatric trials that were driving the rate up. So, the main takeaway from this research is that you cannot take a general level of diversity as adequate for all diseases. You really have to zoom in on the specific indication to understand what constitutes good diversity or representative diversity for that disease.  Dr. Carol Brown: I'd like to ask both of you what do you think about that - what the bar should be. Because Mr. Bebi, you mentioned using the census distribution of races in the population, but I think a lot of us in the cancer field feel like that maybe isn't the right bar. Maybe the bar should really be what is the cancer burden distributed according to self-identified race, ethnicity, or other categories. And when you look at that, I think you find some different statistics. So, Dr. Lopez, could you comment about what your work has shown you about the current state of representation of diverse people affected by cancer in cancer clinical trials, and maybe get a little bit more into what you were saying earlier about the definition of race and the challenge of determining race, etc. Dr. Ana Maria Lopez: We really need to look closely at the data, and that looking at therapeutic trials and at specific populations can be really important. Now, we're a big country, so there can be - what is the catchment area that you serve? And in that catchment area, what are the cancers you're treating, and in which populations are at greatest risk? But right, sometimes it may not be - let's say the population is 10%x, but if that population is at higher risk for a certain disease, to really get granular about the understanding, I need to recruit more people that are from that greater-risk population. So that's where I think it's so important to know the population, to have connections with the community. And actually, the community can say, “Hey, this is what you may want to be studying because this is what impacts us.” Ted Bebi: If I can speak on the research side as well, the best way to ensure representative diversity is to have a very solid understanding of the natural prevalence of a disease. We need to be able to understand what the risk populations are and, even further, what does the mortality look like? Are there differences in how different patients are experiencing the disease further on, not just how they're getting the disease and how often they're getting the disease? So it needs to look different for every single indication. And even with the oncology, for example, the two largest indications in clinical trials for oncology, lung cancer and breast cancer, they also look slightly different. With lung cancer, and our research showing at 8% black participation and breast cancer being a little bit higher at around 11%. So, we always need to take into consideration that incidents include prevalence, include mortality. And yes, the golden standard should be can we build a clinical trial that reflects the actual representative diversity of the disease in the real world? That is what we're striving for. Dr. Carol Brown: I would agree with that. I would also add, though, that there may be some specific cancers for which you want to have an even greater representation of a particular group because it might be directly related to the question you're trying to answer. So, for example, you mentioned breast cancer, so I think most of the audience is probably aware that young women who self-identify as black tend to have a higher mortality from breast cancer. And this is believed to be because they are more likely to get triple-negative breast cancer. And so one of the strategies we've looked at at our cancer center is for trials specifically for triple-negative breast cancer, trying to overrepresent women who self-identify as black or have African ancestry in those trials because we're specifically trying to make sure that we do something to narrow that gap in survival from breast cancer that they experience. So, I think that, as you all mentioned, I think what we can take from this is it's really important to look closely that there are different layers and subtleties that we have to take into account.  So, I think we've clearly established that there is underrepresentation of diverse groups. But let's talk about why. So why do we think that different self-identified races and ethnicities or age groups or socioeconomic status background people are underrepresented in clinical trials? What are some of the reasons in your experience for this, Dr. Lopez? Is it funding outreach? What are the main barriers that you've experienced in terms of getting diverse populations to participate in clinical trials? Dr. Ana Maria Lopez: Maybe all of the above. But one of the things, and one of the things that we're working on, is when a person comes in and you have the trauma of the diagnosis. And they're offered a study, and there may be suspicion of the health care system, that may not be the best time to really talk and educate around a clinical trial. So, if people receive the education, learn about clinical trials before that acute event, then they can come in more prepared. So, one is just the concepts of randomization, double blind in the setting where there may be distrust of the healthcare system may be difficult. Also, some of the clinical trials, and I'm sure everyone has studies where the person needs to be at the clinic for about 12 hours getting blood draws. And people have other responsibilities, and they may not have the support mechanisms for transportation, for childcare, for elder care. And if you're taking two to three buses and, you know, here I am in Center City, Philadelphia, and you need to take two to three buses to get home at 07:00, that could be a deterrent to getting on a clinical trial.   So, there are lots of clinical factors, social factors, experience with the studies, and also how we design the studies. Can we design studies so that we are more inclusive in the criteria? So, I think lots of questions, and then certainly there are clinician factors. There could be bias that we all have that maybe we don't offer studies to certain people, so something for us to be very introspective about as well. Dr. Carol Brown: So, Mr. Bebi, could you comment specifically on, with the research that you've done, are there some barriers on the side of the sponsors of the trials or in terms of industry that you found and that you found in your work at Medidata, maybe really affecting the ability of diverse people to participate in clinical trials? Ted Bebi: Dr. Lopez did a really good job at presenting what we consider patient-level barriers, such as mistrust in the healthcare system. Logistical issues such as taking time off from work, transportation, or feeling that the investigators running the trials don't fully represent the patient. But the industry-level barriers are just as important. A lot of companies are making decisions on what good diversity should look like and where they can find more diverse patients based on incomplete data sources such as disconnected external data, or they might be limited to data from the companies.  Dr. Carol Brown: Great. So, Dr. Lopez, what do you think individual physicians can do, or individual investigators can do to improve the diversity of representation in cancer clinical trials? Dr. Ana Maria Lopez: Certainly, being circumspect, being aware of our own biases, our own approaches. But as a health system, I think we need to think about: How can we make it easy to enroll people into trials? So are there ways, if this is, for example, a study for people at this stage of cancer, that all of those patients could be screened in the electronic record? Let's have our electronic tools work for us so that we identify patients that are meeting the study criteria and then connecting the patients, the study, and the investigators together. So, this way, by having our systems identify potential participants, there's a less chance of there being that personal bias. The research team can come to the doctor, to the oncologist, let's say, and say these are folks that are eligible. What do you think? So, in a way, setting up systems to help with the recruitment would be very helpful. Dr. Carol Brown: Mr. Bebi, can you comment from the standpoint of specifically– because you focus on this– the importance of data, the data, how to capture the data about race or ethnicity or whatever the demographic diversity variable is, what can individual investigators do to really address the challenges around collecting this data and sharing it? Ted Bebi: Often, race and ethnicity data is not even captured at all. So, if we want to understand this issue better and improve upon it, we need better data inputs in order to produce this large-scale research that will help us ultimately advance the issue and not just rely on anecdotal information. Dr. Carol Brown: Are there any technologies or things that you came across in your specific work that can help with this ability to capture this type of data and to share it? Ted Bebi: I think it has more to do with the awareness and the clinician relationship with the patient. And I also think it has to do with sponsors and the way that they design the trial, to begin with, whether or not the race and ethnicity entry is something that they're asking in their electronic health forms. Because if that is not included in the clinical trial, to begin with, then there won't be any incentive to capture that information. Dr. Carol Brown: Dr. Lopez, do you have any specific tips that you would recommend to clinicians who want to improve recruitment of underrepresented groups in their clinical trials? Dr. Ana Maria Lopez: I think one thing that's really important is to be able to have the time. Now, that may not mean that it's all the clinicians' time. It may mean that you have a research coordinator. It may mean that you have a research nurse. It may mean that you give the patient a video that explains the study that they can take home. There can be different ways. Something that I often ask a patient is, “How do you make decisions?” People tell me, “You know, I always go over this with my wife,” let's say, or, “I always discuss this in our family, and then we come to a conclusion.” Because that really helps me to think about how should I best deliver the information so that the patient can really feel I made a good decision and I made a value-congruent decision. So, I think time is critical and to set up our patient experience to really facilitate that type of experience for the patient.  Also, as a reference, I would urge people to take a look at the recent recommendations put out by ASCO and ACCC that talk specifically about increasing racial and ethnic diversity in cancer clinical trials. So, there are lots more strategies, a lot more ideas, and ways to really support clinicians and researchers. Dr. Carol Brown: Mr. Bebi, do you have any specific tips, particularly for trial sponsors, about how they can improve diversity in their clinical trials? Ted Bebi: In terms of companies and sponsors, what they can do if they want to improve diversity in their trials is they need to find and include the right sites that serve the populations that they are looking for. We published research that shows that there is high variability of diverse recruitment based on which sites you are looking at, with some sites providing the highest concentration of diverse patients. So, if diversity is not woven into trial design off the bat and you're not selecting the right sites, you run the risk of not reaching these populations. Companies also need to be willing to put in work to educate and develop sites into clinical trial sites. A clinical trial site is about building trust and relationships and knowing how to be culturally adept at talking to diverse communities.   Dr. Carol Brown: Great. Thank you so much. Well, I want to thank both of you, Dr. Lopez and Mr. Bebi, for a lively discussion on this ASCO Education podcast about diversity in clinical trials.   The ASCO Podcast is where we explore topics ranging from implementing new cancer treatments and improving patient care to oncologist well-being and professional development. If you have an idea for a topic or a guest you'd like to see on the ASCO Education Podcast, please email us at education@asco.org. To stay up to date with the latest episodes and explore other educational content, please visit education.asco.org.  Speaker Disclosures Dr. Carol Brown – None Ted Bebi: Employment – Medidata (a Dassault Systèmes company); Stock and Other Ownership Interest – Pfizer, Eli Lily, Abbvie, Merck, BMY       Dr. Ana Lopez – None The purpose of this Podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this Podcast express their own opinions, experience, and conclusions. Guest statements on the Podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    

Adoption of new clinical trial technologies is critical to success. These innovations can lift patient burden, improve patient engagement, and increase equity and access to clinical trials. In this episode, Kelly McKee and Alicia Staley of Medidata are joined by Irfan Khan, MD, founder and CEO of Circuit Clinical, to discuss clinical trial technology adoption across patients, care teams, trial sites, and researchers and the need for industry buy-in, especially around decentralized trial technology. Dr. Khan is a cardiologist who has served as a principal investigator on both therapeutic and device clinical trials for more than a decade. He is passionate about improving diversity in clinical trials, increasing community engagement, and fostering the patient experience through education and empowerment. Over the last six years, he has overseen Circuit Clinical's growth to reach more than 2.5 million potential participants across 60+ active research sites.

Messaging can't be one-size-fits-all. Find what you want to communicate to your clients. In this episode of Marketing Mondays, Andreea Borcea interviews David McKie, VP of Life Sciences Marketing of Medidata Solutions at Dassault Systèmes. He speaks of how the acquisition process of Medidata and the aftermath of the COVID-19 pandemic paved the way for how he and his team would approach demand marketing. David explains the strategy that Medidata has taken with customers, talking to them about their challenges and engaging with them before offering them solutions or technology. He talks about virtual versus in-person tools and the importance of customized messaging to have the desired dynamic and pull with the target customers. Finally, he discusses innovation in clinical trials and how he has witnessed large and small companies embrace it differently. Tune in to this episode to learn how David leads demand marketing at Medidata! Click this link to the show notes, transcript, and resources: outcomesrocket.health

When it comes to patient recruitment strategies, there is no one-size-fits-all approach. So how do you raise clinical trial awareness and develop innovative solutions for recruitment that break down silos and improve patient outreach? In this episode, Kelly McKee and Alicia Staley of Medidata are joined by Tricia Barrett, Chief Operating Officer at Praxis & Crowley Webb, to discuss what an efficient direct-to-patient recruitment campaign looks like. Learn how to drive diverse patient recruitment by moving from transactional, traditional strategies to innovative, people-focused approaches. Tricia oversees all Praxis operations from proposal generation through completed, enrolled studies. Her experience encompasses a wide range of therapeutic areas and strategies. Tricia brings a unique approach to patient recruitment that focuses on sound science and innovative execution, while always keeping the patient experience top of mind.

Is your product truly inspired by patient insights? Patient centricity is more than just a buzzword: it's a movement. So how do you make sure your products improve the patient experience in clinical trials and alleviate patient burden? In this episode, industry experts Kelly McKee and Alicia Staley are joined by Paul Chang, VP of Design at Medidata, to map the future of product design in clinical trials. Learn how Medidata's patient advocates directly impact UX design to drive patient centricity across products. Paul has spent over 20 years across a diverse range of product and design initiatives. In his role as VP of Design, he is responsible for how products and services are experienced by customers, partners, clinicians, and patients; this includes leading design strategy and building Medidata's capabilities and reputation as a design-driven company.

The last five years have seen large innovations throughout drug development and clinical trial life cycles—from finding a target and designing the trial, to getting a drug approved and launching the drug itself. The recent use of mRNA vaccines to combat covid-19 is just one of many advances in biotech and drug development. Whether in preclinical stages or in the commercialization of a drug, AI-enabled drug development is now used by an estimated 400 companies and has reached a $50 billion market, placing AI more firmly in the life sciences mainstream. “Now, if you look at the parallel movements that are happening in technology, everyone's in consensus that the utility of what AI can do in drug development is becoming more evident,” says senior vice president at Medidata AI, Arnaub Chatterjee. The pandemic has shown how critical and fraught the race can be to provide new treatments to patients, positioning the pharmaceutical industry at an inflection point, says Chatterjee. And that's because drug development usually takes years. Evidence generation is the industry-standard process of collecting and analyzing data to demonstrate a drug's safety and efficacy to stakeholders, including regulators, providers, and patients. The challenge, says Chatterjee, becomes, “How do we keep the rigor of the clinical trial and tell the entire story, and then how do we bring in the real-world data to kind of complete that picture?”   To build more effective treatments faster, drug and vaccine companies are using data iteratively to improve understanding of diseases that can be used for future drug design. Bridging gaps between clinical trial and real-world data creates longitudinal records. AI models and analytics can then be used to enable feedback loops that are key for ensuring safety, efficacy, and value, says Chatterjee. “We want to create safe and expeditious access to therapy,” says Chatterjee. “So we really have to meet this moment with innovation. With all the new advances happening in drug development, there's no reason why technology and data can't be there.”   This episode of Business Lab is produced in association with Medidata.   Related resources ●     Integrated evidence, Medidata ●     Why artificial intelligence could speed drug discovery, Morgan Stanley

As a patient, who owns your clinical trial data? Patient participation is the foundation of clinical trial research. But in today's world, patient access to data is limited and siloed. How do researchers ensure patient data return is the standard operating procedure and information is shared with trial participants? In this episode, Craig Lipset sits down with Kelly McKee and Alicia Staley of Medidata to discuss the challenges of data return and how to improve patient access and clinical trial data transparency. Craig is an advisor, educator, advocate, and innovator focused on novel solutions for clinical trials and medicine development. He is the founder of Clinical Innovation Partners, Co-Chair for the Decentralized Trials & Research Alliance, and Vice Chair of the MedStar Health Research Institute. 

Would you be more inclined to take part in a clinical trial if you could do so in the comfort of your own home? This is now a possibility for some trial areas as apps, sensors, and monitors allow for real time tracking of patients - but how accurate are results when trials are conducted out of a controlled environment? And how is Singapore positioned to tap into growth in the clinical trial sector? Rachel Kelly speaks to Edwin Ng, Senior Vice President, Asia Pacific, Medidata to find out. See omnystudio.com/listener for privacy information.

Medidata recently hosted a Site Advocacy Group (SAG) where SCRS member sites offered feedback on budgeting and payments for clinical trials. Tina Mincher, Director, Client Strategy, Clinical Trial Financial Management at Medidata and Edward Czerwinski, Senior Medical Director, FutureMeds, join us to discuss what was learned from a service provider and site perspective. Hear some of the top financial struggles for sites and how sites and industry partners can work together for better transparency with trial budgets and payments.

  Joe Dustin is Vice President of Product Strategy and General Manager for eCOA and Decentralized trials at Medable.  He is responsible for the go-to-market strategy around Medable's solutions and is working to define what decentralized trials will become with the professionals who are living it every day. For 20 years, Joe has been in the Clinical Trials Industry at the intersection of Technology, Innovation and Science. He has held a number of roles in IT, Project Management, Solution Consulting, Product Development and Sales at tech companies like Medidata and CRF Health, and most recently was the Head of Clinical Innovation and Change Management at Bristol Myers Squibb. In this episode we discuss decentralized clinical trials (duh), the financial implications for sites, the disconnect between sponsor, vendor and site, the value proposition of site technology, and so much more.

Did you know that it is possible to transform your health data into artistic expression? Justus is here to tell you how having something tangible about your body's information helps in healing healthcare. In today's episode of The Create and Grow Podcast, we speak with Justus Harris.Justus Harris is the epitome of what it means to combine disciplines to make a greater impact in the world. They are an artist, educator, and health advocate.  After their Type 1 Diabetes diagnosis, Justus founded MedSculp, which from 2016-2020 used the expertise of doctors, entrepreneurs, and technologists to create data visualization experiences for patients to better understand their complex medical history.  Justus Harris has taken this initiative into patient-experience consulting work with clients in clinical trials such as Medidata, where he is a Patient Insights Board member.  In corporate consulting Justus is a facilitator specializing in the patient perspective in design-thinking, empathy, and using creativity in multi-disciplinary teams.   Their international art practice has taken them to the Kennedy Center as a Citizen Artists Fellow and Berlin as a European Commission Recipient. As an educator, Justus focuses on public speaking and facilitation, including features at TEDx and Stanford Medicine X.  Justus supports individuals 1x1 through coaching with professionals in career transition who are prioritizing their creative practices to transform their lives and the world. Topics Covered on this episode of The Create and Grow Podcast: 06:20 A Creative Skill called Transformation09:30 Dr. Daniel Siegel: Interpersonal Neuro-Biology11:25 Art Transforming Health14:30 Third Gem of Intercultural Creativity: Observation15:40 Draw to Increase Observational Skills17:12 Redefining Creativity18:48 Transforming Diabetes 1 Data into Artistic Expression22:30 Highlighting the sculpture with Dr. Katz' Keeping Your Brain Alive24:29 Build Your Creative Space to Innovate Any Workplace25:05Justus' Sculptures on Exhibits26:48 Art is Solving the Problem28:16 Tips from Justus for People to Dive in Their Artistic Creativity Subscribe:  Spotify | YouTube  Connect with Genein Letford: Visit CAFFE Strategies Visit GeneinLetford.com Follow Genein on Facebook  Connect with Justus Harris: Website:  JustusHarris.com  TEDx Talk: https://www.ted.com/talks/justus_harris_artists_are_key_to_healing_healthcare LinkedIn:  https://www.linkedin.com/in/justusharris/  #PowerOfJournaling #PerspectiveShifting #SeeingYourLifeFromAnOutsidePerspective #CAFFEStrategies #Intercultural #Diversity #InterculturalCreativity #Creativity #InterculturalCreativity #innovation #Mental Health #WhyArtistsAreaKeyToHealingHealthcare

Julia Maués was diagnosed with breast cancer in 2013 while pregnant. Following the birth of a healthy baby boy, Julia did tests she couldn't do while pregnant and discovered the cancer had spread to her brain, liver, and bones. After many treatment setbacks, her cancer began to respond to treatment. After adjusting to this new reality, she made it her mission to use this “bonus time” to make an impact in the lives of others dealing with cancer and consequently creating something positive out of a very tragic experience. She has found meaning and purpose in working with patients and researchers to make cancer research more patient-centered, innovative, and inclusive. Julia is a co-founder of GRASP, a program connecting researchers and patient advocates, and elevating patients as a critical voice in the research process as the experts in living with cancer. She's also a member of a patient-led effort to shine a light on dosing for therapies given to metastatic breast cancer patients, therightdose.org. Lastly, Julia is very passionate about using her privilege as a white woman to work towards ending disparities for patients of color, especially Black women with breast cancer. She is a founding member of the #InclusionPledge and has pledged to not participate in advocacy initiatives, conferences, panels, projects, that don't include the perspective of patients of color. At age 43, Sheila Marie Johnson — a retired Air Force Senior Master Sergeant and mother of one was diagnosed with stage IV HER2-positive, hormone receptor-positive breast cancer in December of 2009. Since being diagnosed with metastatic breast cancer, Sheila has undergone many aggressive treatments including a bilateral mastectomy and many rounds of chemotherapy. She is an alumnus of A Fresh Chapter with trips to India and Kenya and is a Young Advocate for Living Beyond Breast Cancer Young Women's Initiative Program. Sheila is a consumer reviewer for the Department of Defense Breast Cancer Research Program and METAvivor, where she reviews proposals for funding and she is a member of the Patient Insight Board for Medidata. Sheila is a facilitator and a Board Member for Breast Cancer Recovery and a 2020 participant in the Escape to Thrive Leadership Conference. She's a Komen Scholar and on the Komen Advocates in Science Steering Committee. Sheila is featured in a Pfizer documentary called A Story Half Told and featured in Breast Cancer Wellness Magazine. Her platform raises awareness about black breast cancer and the health/racial disparities that exist against black women/men in the medical community. She dedicates her life's mission to her mother and father, Dillard and Grace Johnson.

Patient Advocate, Interdisciplinary Artist, Innovation Consultant Devoted to Connection and Repair. Liza Bernstein, a Third Culture Kid who is NED (No Evidence of Disease) after three cancers is a patient advocate, interdisciplinary artist, and innovation consultant devoted to connection and repair. Liza Bernstein's advocacy serves a global audience via social media, conference attendance, speaking and media engagements, peer mentoring, and relationship-building. She also collaborates, co-designs, and advises across the multi-stakeholder healthcare spectrum to break down silos, foster understanding, promote education and empowerment, and accelerate change. In late 2010, Liza began to explore the worlds of breast cancer and healthcare innovation on Twitter and never looked back. Her work at the intersection of healthcare innovation, technology, and human-centered design has made impact at groundbreaking companies and organizations including Cure Forward, Science 37, CanSurround, Symplur, Medidata, Omicure, and BioNews. Liza's background in human-centered design includes projects with RGA/LA, IDEO, Bruce Mau, and Medicine X Design Studios. A Stanford Medicine X founding ePatient scholar, advisor, and former board member, Liza has given talks internationally on topics including Patient-Centered Design; Dignity in Healthcare; Mental Health and Cancer; Death and Bereavement; Social Media and Patient/Clinician Relationships; and Shared-Decision Making. Liza, who is also an interdisciplinary artist (ceramics, Capoeira Angola, writing), is a TCK (Third Culture Kid) who grew up in South Africa, France, and the US. She is passionate about connecting and collaborating across vastly differing cultures and digs deep into her life experience and expansive creative training to do whatever it takes to facilitate understanding and communication—she's no stranger to improv, which has the added benefit of yielding lots of laughs. Recently, Liza executive produced, directed, and hosted A Window Into Rare, Rare Disease Day Panel Discussion at BioNews, where she was the Senior Director of Patient and Community Engagement. She is currently preparing a talk on Innovation in Surgery from the Patient Point of View for the Inworks Innovation Initiative, University of Colorado Anschutz Medical Campus.

At age 43, Sheila Marie Johnson — a retired Air Force Senior Master Sergeant and mother of one was diagnosed with stage IV HER2-positive, hormone receptor-positive breast cancer in December of 2009. Since being diagnosed with metastatic breast cancer, Sheila has undergone many aggressive treatments including a bilateral mastectomy and many rounds of chemotherapy. She is an alumnus of A Fresh Chapter with trips to India and Kenya and is a Young Advocate for Living Beyond Breast Cancer Young Women's Initiative Program. Sheila is a consumer reviewer for the Department of Defense Breast Cancer Research Program and METAvivor, where she reviews proposals for funding and she is a member of the Patient Insight Board for Medidata. Sheila is a facilitator and a Board Member for Breast Cancer Recovery and a 2020 participant in the Escape to Thrive Leadership Conference. She's a Komen Scholar and on the Komen Advocates in Science Steering Committee. Sheila is featured in a Pfizer documentary called A Story Half Told and featured in Breast Cancer Wellness Magazine. Her platform raises awareness about black breast cancer and the health/racial disparities that exist against black women/men in the medical community. She dedicates her life's mission to her mother and father, Dillard and Grace Johnson.

Jackie Kent, Chief Customer Officer at Medidata, a Dassault Systèmes company, shares background on the SCRS Diversity Awareness Program and takeaways from hosting diversity-focused discussions with sites, patients, and industry partners. What strategies are working, and what can we expect next to ensure better diversity in clinical trials? Listen to this episode to learn more and be sure to join us at the inaugural Diversity Site Solutions Summit in Austin, Texas this May! https://diversitysitesolutionssummit.com/

Today, we revisit one of our favorite episodes from 2021 featuring Glen DeVries, Co-CEO at Medidata, the most used platform for clinical trials worldwide. Tragically, Glen died in a plane crash in November. We remember him for his great work, including his book, "The Patient Equation: The Precision Medicine Revolution in the Age of COVID-19." Glen was unique in the annals of woke brainiacs who lived in the hyper multi-syllable world of science, data, and related semantic geekery AND YET he was hyperaware that average Jane's and Joe's like you and me prefer to actually understand the words emanating from the mouths of "science people" that may or may not be critical in helping us make life-altering medical decisions. Enjoy our conversation about Moore's Law and how it applies to the intersection of biology and technology, how we might need to reframe the concept of an impending robot apocalypse, and whether HAL from 2001: A Space Odyssey could be our future gatekeeper to a clinical trial. More on Metadata at medidata.com. More on us at OffScrip.com and @MZOutofPatients, @MatthewZachary, @VaxOnPod, and @OffScripMedia on Twitter. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Medidata technology has helped to bring COVID-19 vaccines and treatments to market in record timelines and the company was the first to have launched a fully end-to-end Decentralised Clinical Trials (DCT) offering. Decentralised clinical trials, described as the ‘new normal' and the future of clinical research, harness remote technologies to enable patients to participate in clinical trials from their home or preferred location, decreasing patient burden and offering greater flexibility as well as increasing the reach to patients around the world. Lisa Moneymaker is the Senior Vice President of Clinical Operations Technologies for Medidata Solutions. She has over 20 years of pharma, biotech, and medical device industry experience, delivering complex systems solutions in support of excellence in clinical trial execution. Paul O'Donohoe is Senior Director, eCOA Product and Science at Medidata. He is responsible for developing the company's scientific expertise for electronic clinical outcome assessments, and mobile health in clinical trials, and supports internal teams and sponsors around the implementation of industry and regulatory best practices in studies using eCOA. Listen to this podcast to find out more about why decentralised clinical trials are becoming increasingly significant, how the pandemic has affected the clinical trials space, the importance of the patient experience and what clinical trials will look like in the future.

   On this episode we are talking about the deaths of famed Memphis rapper Young Dolph and the beef conspiracies surrounding his murder.     We are talking about the sudden death of late trap and drill rapper from Illinois, Juice WRLD and some mysterious circumstances surrounding his death.    And we are also talking about Glen de Vries, the owner of Medidata and one of the astronauts who flew on the Blue Origin expedition's death days after that launch.    Join us and let us tickle your titillatory tentacles of terrific tantric and traumatic tinkering for thought tomb's (your brain) and let's discuss! patreon.com/theilluminatitelegraph for adfree audio Full videos on our youtube  Death Metal: Death of Skepsis                      Golgothan                             Indy Rock : Alfred and the Teddinators               Hip Hop :  CoolDill                        Metamorphicon                          Emo    : Dillon Crozier  Show Notes:   https://www.cnn.com/2021/11/12/business/glen-de-vries-death/index.html https://www.medidata.com/en/leadership/glen-de-vries https://www.medidata.com/en/veeva-litigation-faq https://www.bbc.com/news/newsbeat-51218254 --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/theskepsistelegraph/message Support this podcast: https://anchor.fm/theskepsistelegraph/support

Update (11/12/2021): We are devastated to learn of the sudden passing of Glen de Vries. He was a thoughtful, brilliant guest whose innovative ideas we were lucky enough to hear firsthand on the show. Our deepest condolences to his family. He will be missed. Glen de Vries, Vice Chair for Health and Life Sciences at Dassault Systèmes and Founder and former CEO of Medidata, the first cloud based system supporting global clinical trials research. An astronaut aboard Jeff Bezos' recent Blue Origin rocket flight with William Shatner of Star Trek fame, de Vries points to the scientific advances from the nation's space program fueling the technologies that now support telehealth and precision medicine. Also author of The Patient Equation, he predicts a dramatic period of exponential growth in scientific and biologic discovery post-pandemic. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Update (11/12/2021): We are devastated to learn of the sudden passing of Glen de Vries. He was a thoughtful, brilliant guest whose innovative ideas we were lucky enough to hear firsthand on the show. Our deepest condolences to his family. He will be missed. This week hosts Mark Masselli and Margaret Flinter speak with Glen de Vries, Vice Chair for Health and Life Sciences at Dassault Systèmes and Founder and former CEO of Medidata, the first cloud based system supporting global clinical trials research. An astronaut aboard Jeff Bezos' recent Blue Origin rocket flight with William Shatner of Star Trek fame, de Vries points to the scientific advances from the nation's space program fueling the technologies that now support telehealth and precision medicine. Also author of The Patient Equation, he predicts a dramatic period of exponential growth in scientific and biologic discovery post-pandemic.

Canary Cry News Talk #410 - 11.12.2021  GEN NARRATIVE: Winter Waxxine Wonderland, Klaus' Great Narrative, Ecopreneur - CCNT 410 WEBSITE/SHOW NOTES: CanaryCryNewsTalk.com LINKTREE: CanaryCry.Party SUPPORT: CanaryCryRadio.com/Support MEET UPS: CanaryCryMeetUps.com ravel Podcast (Basil's other podcast) Facelikethesun Resurrection (Gonz' new YouTube channel) Truther Dating experiment   INTRO 3:09 Clip: Amal update Clip: Biden on when his knee grows    FLIPPY 15:45 “Can't Help Myself” robot arm art is bloody (Truth or Fiction)   GREAT RESET…NARRATIVE 24:35 Klaus Schwab announces the GREAT NARRATIVE (RT)   Note: WEF says we need “Ecopreneur Revolution” (WEF) Robots already taking over in Great Resignation (ZDNet)   COVID19/I AM WACCINE 45:20 Clip: Pfizer CEO Bourla confusing answer from question about communication Virginia pharmacy incorrectly administers covid waccines to 112 children (CNBC) Why are cases surging in highly waxxed areas? (Yahoo News) [CDC - MMWR, MedRxiv Israel]   Party Pitch BREAK 1: Executive Producers, Paypal, Patrons 1:20:28   IT WILL KILL 1:45:43 Man who traveled to space with Bill Shatner dies in plane crash…Medidata sus (KRQE)   CYBERPANDEMIC [Results] Cyber Polygon Results from WEF (Sociable)   CHINA 2:03:19 China military documents reveal why they invested in AI (Breaking Defense) China's new military toy might dominate pacific (RT)   BREAK 2: Art, Reviews, Jingles, Meet Ups 2:17:42   GEOENGINEERING 2:44:58 Clips: Climate prophetess of the NWO from 1800's (NBC, Storyteller)   SPACE POPE REPTILIAN 3:00:47 Francis says if we don't fight climate change, we will face God's judgment (Jesuit Review)   ADDITIONAL STORIES: Miso Robotics Native Ad (Newsweek…the took it down…haha) Robot that paints wall with one million spots (Interesting Engineering) Answering FOIA, CDC has no record of unwaxxed spreading virus after testing positive Miami, first city to give Bitcoin dividends to residents (CoinDesk) Inflation rose 6.2% in October, largest in 30 years (Wapo) COP26 draft for final deal towards 2030 (Aljazeera)  Corporate Execs call for White House to fight inflation (Politico) 10 states sue Biden over mandates (Reuters) Human trials for ebola waccine set to begin (Guardian) Why the Green New Deal should be scrapped (Guardian Opinion) Softbank raises $188 million for robot arm (Deal Street Asia) Exorcist and Demonologist breaks down Astroworld satanism (DailyCaller)   PRODUCER'S ep410: Executive Producer Brett H**   Ass. Executive Producer EmiBob* Amanda P*   Producers Kathleen C, LittleWinged1, Spearsdesert, Denise W, Scott K, Gail M, Heatheruss , 57 Chevy Girl, Sir Sammons Knight of the Fishes, Morv, Sigrah the Beast, A Unique Jewelery Boutique, Sir Casey the Shield Knight, Doughty the Coyote, JC, Jackie U, Andy K, Green Mountaineer, Veronica D, Shagen, Child of God, DrWhoDunDat, Runksmash, Ciara   Patreon Kay B ebonie F   ART: Dame Allie of the Skillet Nation Sir Dove, Knight of Rustbeltia Ryan N   MICROFICTION Runksmash - Basil, Gonz and NFG watch as the MEGA BASILs battle. The city is in ruins as finally one is victorious limping he goes to his maker, the original B. A. S. I. L. leaves the collective “Did I… save you…” he asks falling at Gonz's feet, battery exhausted   Epilogue: At some point in the past a familiar robotic father pats the shoulder of a young man “Now son, if you ever time travel it's inevitable you're going to have to go back and kill your past self, so just be grateful for the seconds you have. ”

Canary Cry News Talk #410 - 11.12.2021  GEN NARRATIVE: Winter Waxxine Wonderland, Klaus' Great Narrative, Ecopreneur - CCNT 410 WEBSITE/SHOW NOTES: CanaryCryNewsTalk.com LINKTREE: CanaryCry.Party SUPPORT: CanaryCryRadio.com/Support MEET UPS: CanaryCryMeetUps.com ravel Podcast (Basil's other podcast) Facelikethesun Resurrection (Gonz' new YouTube channel) Truther Dating experiment   INTRO 3:09 Clip: Amal update Clip: Biden on when his knee grows    FLIPPY 15:45 “Can't Help Myself” robot arm art is bloody (Truth or Fiction)   GREAT RESET…NARRATIVE 24:35 Klaus Schwab announces the GREAT NARRATIVE (RT)   Note: WEF says we need “Ecopreneur Revolution” (WEF) Robots already taking over in Great Resignation (ZDNet)   COVID19/I AM WACCINE 45:20 Clip: Pfizer CEO Bourla confusing answer from question about communication Virginia pharmacy incorrectly administers covid waccines to 112 children (CNBC) Why are cases surging in highly waxxed areas? (Yahoo News) [CDC - MMWR, MedRxiv Israel]   Party Pitch BREAK 1: Executive Producers, Paypal, Patrons 1:20:28   IT WILL KILL 1:45:43 Man who traveled to space with Bill Shatner dies in plane crash…Medidata sus (KRQE)   CYBERPANDEMIC [Results] Cyber Polygon Results from WEF (Sociable)   CHINA 2:03:19 China military documents reveal why they invested in AI (Breaking Defense)

Introducing Season 2 of Clinical Minds! An entire season dedicated to why diversity in clinical trials is so important and what's being done to improve participation among underrepresented populations. To kick things off, host Paul Oestreicher chats with Jackie Kent, evp and chief customer officer at Medidata, a Dassault Systèmes

Update (11/12/2021): We are devastated to learn of the sudden passing of Glen de Vries. He was a thoughtful, brilliant guest whose innovative ideas we were lucky enough to hear firsthand on the show. Our deepest condolences to his family. He will be missed. This week hosts Mark Masselli and Margaret Flinter speak with Glen de Vries, Vice Chair for Health and Life Sciences at Dassault Systèmes and Founder and former CEO of Medidata, the first cloud based system supporting... Read More Read More The post Rocketing with Captain Kirk To A New Frontier: Astronaut Glen de Vries on New Era of Innovation In Space Travel and Health Care appeared first on Healthy Communities Online.

*Please note: this episode was recorded prior to Glen's confirmed space flight on Jeff Bezo's Blue Origin flight. As you'll hear his passion for space travel has reigned true for a number of years, so we're delighted he has finally been able to fill his life-long goal :-)Medidata's co-founder (& currently Dassault System's Life Sciences and Vice-Chair) dives into his ever exciting world of entrepreneurship, space travel, flying planes and pretty much anything you can imagine. He shares key tips and learnings that allowed him to turn a bedroom idea into a multi billion dollar corporation, whilst being able to fulfil personal (and fun) ambitions at the same timeGlen's book, The Patient Equation is available for purchase on Amazon using the link below - . Royalties from the sale of the book will be donated to Conquer Cancer, the ASCO Foundationhttps://www.amazon.com/Patient-Equation-Data-Driven-Precision-Medicine/dp/111962214XPlease subscribe to https://edgingahead.buzzsprout.com as further episodes are released in this seriesA special thanks to Nicole Pariser for her help with this production!

An interview with Kelly McKee from Medidata on transforming the patient clinical trial experience.

Global Liver Institute Founder and CEO Donna Cryer hosts Medidata Vice President Alicia Staley, knowRx co-fonder and Chief Medical Officer Dr. James Powell and Global Liver Institute Director of NASH programs Jeff McIntyre in an eye-opening discussion about what it takes to recruit diverse patients into clinical trials.The first two conversations in this series focus largely on patients. This one broadens the scope to address what physicians in underserved communities must do to shape a culture of participation and how drug developers and community advocates can support these goals and activities.

Global Liver Institute Founder and CEO Donna Cryer hosts Medidata Vice President Alicia Staley, knowRx co-fonder and Chief Medical Officer Dr. James Powell and Global Liver Institute Director of NASH programs Jeff McIntyre in an eye-opening discussion about what it takes to recruit diverse patients into clinical trials.In this conversation, the group discusses the importance of building a culture within the patient community that encourages curiosity and interaction by providing sources of information and openness. Listen as these opinion leaders and experts in encouraging broad patient participation describe the principles that underlie their actions.

Global Liver Institute Founder and CEO Donna Cryer hosts Medidata Vice President Alicia Staley, knowRx co-fonder and Chief Medical Officer Dr. James Powell and Global Liver Institute Director of NASH programs Jeff McIntyre in an eye-opening discussion about what it takes to recruit diverse patients into clinical trials. In this conversation, the group discusses why motivating diverse patient populations is key to creating appropriately diverse clinical trial populations in NASH and NAFLD. Alicia Staley describes her key principles as "collaboration and building collateral." Listen as she and the other panelists discuss actions and programs that are key to success, including a primer on what not to include as patient qualification critera.

Global Liver Institute Founder and CEO Donna Cryer hosts Medidata Vice President Alicia Staley, knowRx co-fonder and Chief Medical Officer Dr. James Powell and Global Liver Institute Director of NASH programs Jeff McIntyre in an eye-opening discussion about what it takes to recruit diverse patients into clinical trials.The group shares a wealth of goals, actions and the occasional war-story-gone-bad in describing what we all need to do to enroll a diverse set of patients into clinical trials. The keys revolve around information, communication and transparency, but success or failure lie not only in the goals but also in the details. This is one of our most informative episodes on patient recruitment and communication to date.

One of the most exciting frontiers in medicine is the use of huge amounts of patient data to help design personalized and highly effective individual treatments which never would have been possible before. My Friday Fireside Chat guest, Glen de Vries, is the co-CEO and co-founder of Medidata, a company which provides an analytical platform that has completely transformed the way clinical trials are done, making them faster, better targeted and more effective. He is also the author of the recent book, "The Patient Equation" which promises to give us a glimpse of the data-intensive future of healthcare. --- Send in a voice message: https://anchor.fm/thoughtsparksritamcgrath/message

In this episode we speak with Glen de Vries, co-founder, and co-CEO of Medidata (a Dassault Systèmes company) following an RSM Digital Health Webinar. Medidata is the most-used platform for clinical trials around the world, powering tens of thousands of clinical trials with millions of patients and billions of patient records. Glen is the author of The Patient Equation: The Precision Medicine Revolution in the Age of COVID-19 and Beyond. We discuss the future of clinical trials powered by latest technologies, and the important shift from population based care to individualised care. You can follow Glen on Twitter at @CaptainClinical. All views expressed in this episode are of the speakers themselves. Find out more about the RSM digital council: http://rsm.ac/dhsectionpodcast. Follow the conversation: #RSMdigihealth

Meet: Mike Arbitman, Senior Director, Technology Organization Data and Analytics at Medidata, a technology leader skilled at defining, building, improving, and optimizing data-focused organizations delivering innovative and leading-edge solitons What you'll learn: Modernization of master data management Determining the system of record The changing complexity of data projects If you have any questions for Mike, please feel free to reach out via LinkedIn: https://www.linkedin.com/in/michaelarbitman/

Charlie O'Donnell, Founder & General Partner of Brooklyn Bridge Ventures Charlie O'Donnell has been an active member of the NYC startup community for over 15 years, with a reputation of being the most accessible early stage investor in New York. After being hired as the first analyst at Union Square Ventures and helping to open First Round Capital's first NYC office, he founded Brooklyn Bridge Ventures in 2012. Brooklyn Bridge Ventures has made over 60 investments since it was founded, making it one of the most active funds investing in pre-seed and seed rounds in the city. It often leads or co-leads, investing in a wide variety of startups founded by a diverse pool of founders including The Wing, Petal, Clubhouse, Hungryroot, Canary, goTenna and Imagen, among others. The fund was the first to be launched in Brooklyn--where he was born and raised. Danny Brown, Partner at MaC Venture Capital Danny Brown is Partner at MaC Venture Capital, an LA-based early stage fund focused on technology companies leveraging shifts in cultural trends and consumer behavior in an increasingly diverse global marketplace. Additionally, he is the current Chief of Staff at Atom Factory, where he focuses on leveraging their unique position at the intersection of tech, music, media, and various other industries to the benefit of their portfolio, as well as the surrounding ecosystem. Gyan Kapur, Managing Director at Bayes Ventures and Co-Managing Partner at RTP Seed (RTP Ventures) | B2B Investor Gyan joined RTP Ventures in early 2020 and became co-Managing Partner of RTP Seed, RTP Ventures' fund dedicated to investing in seed and pre-seed stage companies, later in 2020. Prior to joining RTP Seed, Gyan ran Bayes Ventures, an early stage fund with a similar focus. Prior to Bayes Ventures, Gyan was a Vice President at Activate Venture Partners (first investor in Medidata, a $6bb exit) and an active angel investor. Gyan graduated from the MBA program at the Wharton School of Business. Before Wharton, Gyan worked for Gather Health, a chronic disease management startup, and Citigroup where he built and scaled businesses in foreign exchange derivatives, focusing on complex products. Megan Ananian, Investor, Seedinvest Megan joined the Seedinvest team in 2019 after receiving her MBA at Yale School of Management. SeedInvest is an early-stage fund as well as an investment platform connecting founders with a community of over 375k investors. They've invested $200M+ into over 200 companies through Reg CF, Reg D, and Reg A. https://entre.link/EntrepreneurShow --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Learn more about Medidata: https://www.medidata.com/en/

Executive coach, Nadine Mendelek Theimann, PhD, PCC, discusses how mindfulness, compassion and purpose can save corporate Leadership. Since mid-March of 2020, we've faced an expanding global pandemic, associated extreme economic volatility and mass protests over racial injustice. The convergence of these three crises has many business leaders questioning if their leadership skills that they have honed over the years will be the same skills they will need to face the challenges of the "new normal." In this new normal, leadership is more important than ever before – because the best leaders define reality and inspire hope. Host Craig Welch from BlackMoss Partners spoke with Nadine about what type of leader is needed for the new normal. Nadine has coached and counselled many c-suite executives from various industries including financial services, manufacturing, insurance, high-tech and telecommunications. She is an executive leadership coach who has an extensive career in coaching high-profile executives globally in leadership development. Her clients include Facebook, Apple, Blue Shield, Medidata, Texas Instruments, Columbia Sportswear, Groupon, MSCI, and Legalzoom. In addition to her academic credentials in leadership coaching and counselling, Nadine also holds a PhD in Economics and was a Visiting Fellow at Princeton University's Department of Economics.

On this week's Tech Nation, Moira speaks with GLEN DeVRIES, the co-founder and co-CEO of Medidata, a company which has provided data management services for clinical trials for some twenty years. He's talks about “The Patient Equation … the precision medicine revolution in the age of COVID-19 and Beyond”. Then can we diagnose Autism earlier? The average age of diagnosis is 4 years old, but a blood test may reveal autism spectrum disorder as early as 18 months. Moira speaks with BETH DONLEY, the CEO of Stemina Biomarker Discovery.

On this week’s Tech Nation, Moira speaks with GLEN deVRIES, the co-founder and co-CEO of Medidata, a company which has provided data management services for clinical trials for some twenty years. He’s talks about “The Patient Equation … the precision medicine revolution in the age of COVID-19 and Beyond”. Then can we diagnose Autism earlier? The average age of diagnosis is 4 years old, but a blood test may reveal autism spectrum disorder as early as 18 months. Moira speaks with BETH DONLEY, the CEO of Stemina Biomarker Discovery.

On the show today, I welcome Glen DeVries, Co-CEO at Medidata, the most used platform for clinical trials worldwide. Not too shabby, I say. Among many other things, we dig into his new book, "The Patient Equation: The Precision Medicine Revolution in the Age of COVID-19". Glen is unique in the annals of woke brainiacs who live in the hyper multi-syllable world of science, data, and related semantic geekery AND YET he is hyperaware that average Jane's and Joe's like you and I prefer to actually understand the words emanating from the mouths of "science people" that may or may not be critical in helping us make life-altering medical decisions. Yes, Glen is The De-Jaronator, says me. He's a controversial and authentic personality. As a bonus, he's also an 80's nostalgia junkie like me, so prepare for some random pop culture references that you may or may not need to IMDB. We also chat about Moore's Law and how it applies to the intersection of biology and technology, how we might need to reframe the concept of an impending robot apocalypse, and whether HAL from 2001: A Space Odyssey could be our future gatekeeper to a clinical trial. This episode moves pretty fast. If you don't stop and listen around once in a while, you could miss our reference to SneakerNet. More at https://www.medidata.com.

It's the Halloween edition of Health in 2 Point 00 where we round up a bunch of smaller deals plus Medidata buying MC10. The smaller ones include Navina, Nice Healthcare and Vitable (who appear to be the same thing in telehealth), Coa (mental health group classes), and Quit Genius (smoking cessation) which somehow has the tennis playing William sisters on board. But the main question of today is whether Jess DaMassa is wearing a mermaid tail below that wig!

Glen de Vries in his new book "The Patient Equation" says that despite the digital revolution in the way we can capture and analyze data, not much has changed for decades in the how clinical trials are conducted. We spoke to de Vries, co-founder and co-CEO of the clinical trials data platform Medidata, about how clinical trials need to evolve, how technology can be used to improve patient access, and how it can capture new types of data to better answer questions about the safety and efficacy of therapies.

Overview Jason A. Duprat, Entrepreneur, Healthcare Practitioner and Host of the Healthcare Entrepreneur Academy podcast talks to Glen de Vries, Co-CEO and Co-Founder of  Medidata, a leading online platform for clinical trials. He’s also the author of the book, “The Patient Equation.” In this episode, Glen talks about his career as a healthcare entrepreneur and how he pioneered the use of the internet to improve how physicians diagnose and help patients.   Episode Highlights Glen introduces “The Patient Equation,” his book about how the data revolution is transforming healthcare.  He also talks about his childhood, particularly his aspirations and the reasons he pursued research as a career. What inspired Glen to launch Medidata?  How did Medidata become what it is today?  One key to success is to have the right people around you. For Glen, this includes his partners, who made Medidata possible. Glen discusses the challenges Medidata faced and how they moved forward to pursue company goals. Across his career, Glen has always had a conviction for online connection.  He talks about the importance of collaboration between medical professionals, particularly when it comes to research and medicine.  Data is at the center of these collaborations - curating data fit for a purpose and using data to get the right tools in the hands of physicians.  When it comes to data collection, you should utilize data in a way that can actually ‘wake up’ new information. Use big data to find small factors.  Leverage relevant inputs to get the right outputs.  How is Medidata proving to be relevant in the midst of the COVID-19 pandemic?  3 Key Points The future of the healthcare industry rests on the innovation of information dissemination between researchers and healthcare professionals. Collaborative work can help ensure various options will be available for both the physicians and the patients, and a more individualistic approach to treatment can be created. No one treatment equation is highly precise, as every patient is unique. What works for you may not work for others.     Tweetable Quotes “My work experience may seem illogical but I’ve realized they were connected steps I had to go through to reach where I am today.” - Glen de Vries   “The Patient Equation is not a one-size-fits-all formula for treatment success. Rather, it’s a tool to create a better framework to think about.” - Glen de Vries   “It’s important not to give up despite what happens. Surround yourself with individuals who have different experiences that complement each other and trust in their greatness.” - Glen de Vries   References Mentioned Medidata Website: https://www.medidata.com/en/   The Patient Equation: : https://www.medidata.com/en/medidata-institute/thepatientequation/   Dassault Systems: https://www.3ds.com/about-3ds   #HealthcareEntrepreneurAcademy #healthcare #entrepreneur #entrepreneurship #onlineconnection #internet #data #datacollection #thepatientequation #covid19

Glen de Vries, co-CEO and co-founder of Medidata, the most-used platform for clinical trials around the world, shares insights from his new book coming out on September 14, 2020, titled "The Patient Equation: The Precision Medicine Revolution in the Age of COVID-19 and Beyond".

In this PharmaTalk podcast, Kelly McKee of Medidata leads a multi-perspective panel discussion on the challenges and opportunities of adopting a decentralized model for clinical trials and ensuring clinical trial continuity with live video visits. Together they discuss lessons learned from the rapid adoption of technologies to allow for more decentralized trials, how incorporating multiple perspectives highlights areas of growth when utilizing a decentralized approach, and the possibility of hybrid trials becoming the new normal for the near future.  Host: Kelly McKee is the Senior Director of Patient Recruitment and Registries at Medidata Guests:  Anne Marie Mercurio is a patient and research advocate and caregiver.  Rosamund Round is Vice President of PAREXEL’s Patient Innovation Center.  Jeff Kingsley, DO, is the founder and CEO of IACT Health.  For more information about PharmaTalk podcasts, visit theconferenceforum.org. A special thanks to the team at Medidata for their support in presenting this podcast. 

Glen de Vries, is co-founder of Medidata, which was acquired by Dassault Systems for $6B in 2019. Glen is co-founder and co-CEO of Medidata, the most-used platform for clinical trials around the world. Glen has been driving Medidata’s mission since the company’s inception in 1999, “powering smarter treatments and healthier people”. He has recently authored a book called "The Patient Equation: The Precision Medicine Revolution in the Age of Covid-19 and Beyond" where he describes how the digitization of healthcare data will create massive opportunities for personalized medicine. Company Homepage: https://www.medidata.com/ Twitter: https://twitter.com/captainclinical Disclaimer: Remember, the Health Unchained podcast is for informational and entertainment purposes only and we are not providing any sort of legal, financial, or medical advice. Please do your own research and due diligence before making any important decisions related to these matters. Show Notes •Glen's journey from the lab to starting Medidata •Healthcare technology innovation and adoption •Opening up the aperture for better problem solving •Glen’s New book - The Patient Equation - (all royalties donated to Conquer Cancer, the ASCO (American Society of Clinical Oncology) Foundation). •Clinical research innovation •Trends in COVID-19 Clinical Trials/Studies – Lessons for the future? •How can we develop a healthcare system that aligns with the promise precision medicine? •The Importance of incentives in healthcare systems •How can smart devices and wearables change the way doctors practice medicine? •DoD – Device on Dog problem •Will wearables improve patient adherence monitoring during clinical research? •What is the value/benefits of collecting personal healthcare data over time? •Gattaca (the movie) and it’s relation to healthcare data •What are the limits of technology for clinical trials research? •What impact do the big tech players have on the clinical trials industry? •What is Medidata's roadmap for the rest of 2020 and 2021? •Who are the people who have been your biggest influences? •When do you expect to go to space? - https://isglendevriesinspacerightnow.com/ •Final takeaways News Corner On August 26, 2020, in an effort to provide faster Covid-19 test results, the FDA authorized an emergency use of a rapid antigen test that can only be used by authorized labs and patient care settings. To be clear, the BinaxNOW™ COVID-19 Ag Test Card EUA has not been FDA cleared or approved for broad consumer use. A day after Abbott received this emergency FDA approval of its 15-minute COVID-19 test, HHS has awarded it a $760 million contract to produce 150 million tests, the department said this week. The HHS said the tests may be deployed to schools and other "special needs" populations. Healthcare providers using Abbott's test will swab a patient's nose, transfer the sample to a test card. Results become available In just 15 minutes with no instrumentation, using proven lateral flow technology with demonstrated sensitivity of 97.1% and specificity of 98.5% in clinical study. Abbott says they will ship tens of millions of tests in September, ramping to 50 million tests a month at the beginning of October. https://abbott.mediaroom.com/2020-08-26-Abbotts-Fast-5-15-Minute-Easy-to-Use-COVID-19-Antigen-Test-Receives-FDA-Emergency-Use-Authorization-Mobile-App-Displays-Test-Results-to-Help-Our-Return-to-Daily-Life-Ramping-Production-to-50-Million-Tests-a-Month https://www.beckershospitalreview.com/supply-chain/us-awards-abbott-760m-contract-for-rapid-covid-19-tests.html Health Unchained Links Website: https://healthunchained.org Telegram: t.me/healthunchained Twitter: twitter.com/Healthunchaind Bert’s Blockchain and Healthcare Weekly Newsletter: https://bert.substack.com/

Glen de Vries is president of Medidata, the world’s largest platform for clinical research trial data. Medidata is working with several research groups working on the COVID-19 vaccine, including messenger RNA based vaccines in development by Moderna, which was the first vaccine in human clinical trials already in March. The third phase, with 30.000 participants from the US, began end of July. Glen talked about why we have reasons to be optimistic in vaccine development for COVID-19; he also shared some insight into his new book The Patient Equation and explained why clinical trials are complicated and how is technology from platforms to AI helping accelerate trial development and data analysis.    

  Deepa Dahal and Karen Dindial are established biopharmaceutical industry consultants and the co-founders of DKI Health. DKI Health is a healthcare consultancy that offers a range of services, specializing in commercial strategy, policy, healthcare advocacy, and market access. In addition to founding DKI Health, Deepa’s fifteen-year career has included working at Quintiles, IMS Health (IQVIA), and Campbell Alliance (Inventiv). Karen’s work in the healthcare space spans two decades, and also includes time serving at Quintiles, along with Medidata and the Centers for Disease Control and Prevention at the National Institute for Occupational Safety and Health.   Today, Deepa and Karen join me to discuss DKI Health and their shared vision and passion for their consulting work. They share their co-founder relationship and how they use their complementary skill sets to work together effectively and deliver on their brand’s core competencies. Deepa and Karen also highlight the value of relationship building, the importance of patient voices, and their experience as minority women in their industry.       “They don’t hire a company. They hire the people that come with it.” - Deepa Dahal       Today on When She Founded: How Deepa and Karen met and what led them to launch DKI Health The market needs DKI Health addresses and some therapeutic areas the consultancy focuses on The gap that Deepa and Karen saw in terms of women’s leadership in the industry The value that Deepa and Karen have found in having a co-founder The power of relationships and reputation in building a successful brand in a crowded market How DKI Health differentiates itself through patient-centricity and why this matters The different types of stakeholders that DKI Health works with and the types of projects Deepa and Karen enjoy working on The importance of being transparent and honest about what you can and cannot offer as a brand Their early advocates as they launched their consultancy DKI Health’s plans for scaling and expanding the business and insights into DKI Health’s hiring strategy     Connect with Deepa Dahal and Karen Dindial: DKI Health Deepa Dahal on LinkedIn Karen Dindial on LinkedIn DKI Health on LinkedIn DKI Health on Twitter White Paper: Serving Patients, Improving Healthcare: The Growing Role of Patient Advocates         Subscribe, Rate & Share Your Favorite Episodes!   Thanks for tuning into today’s episode of When She Founded with your host, Somer Hamrick. If you enjoyed this episode, please head over to Apple Podcasts to subscribe and leave a rating and review.   Don’t forget to visit our website, connect with Somer on LinkedIn, and share your favorite episodes across social media.                        

Glen de Vries, co-founder and co CEO of Medidata and author of the upcoming book, The Patient Equation: The Precision Medicine Revolution in the Age of COVID-19 and Beyond on how to bring together everything learned about COVID-19 to find treatments and vaccines and what can be done to make sure something like this doesn't happen again.

Glen de Vries cofounded Medidata in 1999, offering SaaS-based clinical development solutions addressing the functioning of customers' clinical trials, and 20 years later the company - which he still leads - sold to Dassault Systemes for almost $6 billion. What a triumph, Glen! Thank you for joining the podcast. Listen in as Glen shares his unique and valuable perspective on the current state and potential futures for the data ecosystem in Life Sciences. Want to stay on the cutting edge of emerging data-driven technologies? Try out Emerj Plus: emerj.com/p1

Anthony Costello, senior vice president of mobile health at Medidata, on what clinical trials look like when people are unable or unwilling to leave home, what this means for the race for a vaccine, and how mobile health technology is paving the way.

How drugs go from a lab, to testing in humans, to your local pharmacy. Here's what's happening in the world of clinical research today, the technology and ideas that are transforming it, and why this matters for patients. Which is all of us. Presented by Medidata.

Clinical trials 101. Alicia Staley, director of patient engagement at Medidata, on why it takes so long to develop drugs and vaccines, what clinical trials are, and how clinical trials can do better for patients.

For our first episode, we explore the use of AI technology in clinical trials and how the COVID-19 pandemic is promoting the use of advanced technologies within the biopharma industry. This episode is led by our host Karen Taylor. Karen is joined by Fiona Maini, Principal Global Science and Compliance at Medidata, and Fareed Melham, Head of Acorn AI Labs at Medidata Solutions. This episode covers: How AI technology is currently being used in clinical trials How regulators are embracing AI in clinical development How regulators are changing their approach in response to COVID-19, including in the acceptance of AI technologies and RWE strategies.    

With the immediate and pressing need for sites to incorporate virtual elements, we talked with Anthony Costello at Medidata on what is being done in the industry to support the new way of performing clinical trials. Discussion centers around unified platforms and how these types of solutions can be beneficial for not only sites and patients, but the entire industry. There are several advantages of unifying services and tools at the site level and we discuss what some of those may look like. 

Capone leads Qlik’s mission to create a data-literate world, one where people, businesses, organizations and governments tackle their most complex challenges with data. Mike has first-hand experience in leveraging the power of data through analytics to transform businesses and entire industries. In addition to his extensive experience in high-growth SaaS companies, Mike was the COO of Medidata Solutions, a publicly-traded provider of SaaS analytics solutions to the Healthcare, Life Sciences and Pharma markets. There he played a significant role in the company’s product development, data science, professional services and go-to-market operations, accelerating its strategy to provide a comprehensive cloud platform that leverages data and analytics to transform clinical trials. Prior to Medidata, Mike held senior leadership positions at ADP including Corporate Vice President of Product Development, CIO, and SVP & General Manager of ADP’s global outsourcing business. He was also head of product development and technology operations for ADP, one of the world’s largest B2B cloud services providers, delivering critical services to over 600,000 companies and 39 million of their staff members worldwide. Capone holds a bachelor of science degree in computer science from Dickinson College and a master of business administration degree in finance from Pace University.

Mark Glover joined Medidata in December 2018 and is the Country Manager Australia and New Zealand, based in Sydney. Mark brings a broad and deep based experience in healthcare, pharmaceutical, medical devices and SaaS industries across Australia, New Zealand, the UK and Asia. He has held executive roles with a diverse range of companies, including Managing Director for iNova Pharmaceuticals, Managing Director Allergan Australia/New Zealand, and General Manager of Serono. His experience spans a broad spectrum of companies, channels, products and services, including start-ups and biotech & medical device companies, through to FMCG, OTC and large pharmaceutical, together with consulting. Mark is passionate about the healthcare industry in all its facets. He has been an active industry contributor, having been a member of AusBiotech, Medicines Australia (including on the Board), Medical Technology Association of Australia, ARCS and ASMI. Mark is focused on patient outcomes driven through digital engagement and transformation with healthcare professionals, patients and consumers.

The lens on HR continues to intensify. McKinsey talks about the G3 the group of three Executives at the top of the company the CEO, the CFO and the CHRO. But how does a CHRO partner successfully with a CEO and the rest of the executive team? That's the topic for this week's episode where my guest is Jill Larsen, Chief People Officer at Medidata on how to transform HR to drive more business value. Jill has over 20 years experience in senior HR roles in companies like Cisco, EMC and SunGard. So she is ideally placed to talk about how the role of the CHRO has changed. In our conversation Jill and I discuss: The key responsibilities of the CHRO in our Modern Age and how these have evolved over the past years The digital transformation of HR and how to bring the rest of the organisation with you along the journey The changing skills requirements for HR professionals We also talk about how you can harness technologies to support this change and transformation And like with all our guests, we look into the crystal ball and ponder what the role of HR will be in 2025 This episode is a must listen for anyone working in HR or Business Leaders who want more from their CHROs and people functions. Support for this podcast is brought to you by pymetrics, to learn more, visit pymetrics.com.

Glen is the President and Co-founder of Medidata Solutions, the leading cloud platform for life sciences research. Glen has been driving Medidata's mission since the company's inception in 1999: Powering smarter treatments and healthier people. His publications have appeared in Applied Clinical Trials, Cancer, The Journal of Urology, Molecular Diagnostics, STAT, Urologic Clinics of North America and TechCrunch. He is a trustee of Carnegie Mellon University, a Columbia HITLAB Fellow, and a member of the Healthcare Businesswomen's Association European Advisory Board.

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano Lagravinese. In questa puntata parliamo di:Biogen, Dassault Systèmes, SSN, Farmacovigilanza attiva, telemedicina, Iperparatiroidismo.Aziende: Biogen, Dassault Systèmes, Medidata, Exom Group, ICON, Phidealive. Persone: Michel Vounatsos (Biogen), Nino Cartabellotta (Gimbe), Luca Li Bassi (AIFA), Luis Alejandro Boccalatte (Ospedale italiano di Buenos Aires).Nuove terapie: Pet/Ct. Patologie: Iperparatiroidismo. Lavoro: Regulatory Affairs Senior Specialist (Milano), Senior CRA (Milano), Clinical Trial Start Up.Il mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/

PharmaPills - Pillole dal farmaceutico: Novità, Curiosità e Lavoro dal mondo del farmaceutico. A cura di Stefano Lagravinese. In questa puntata parliamo di:Biogen, Dassault Systèmes, SSN, Farmacovigilanza attiva, telemedicina, Iperparatiroidismo.Aziende: Biogen, Dassault Systèmes, Medidata, Exom Group, ICON, Phidealive. Persone: Michel Vounatsos (Biogen), Nino Cartabellotta (Gimbe), Luca Li Bassi (AIFA), Luis Alejandro Boccalatte (Ospedale italiano di Buenos Aires).Nuove terapie: Pet/Ct. Patologie: Iperparatiroidismo. Lavoro: Regulatory Affairs Senior Specialist (Milano), Senior CRA (Milano), Clinical Trial Start Up.Il mercoledì alle h 12.00 su Spreaker.com e iTunes.Seguici su: www.telegram.me/pharmapillswww.facebook.com/pharmapills/

What is the state of collaboration today? Is technology making it better or worse, and what is the impact on the #futureofwork? As collaboration-tool provider SLACK readies for what could be an impressive IPO on the heels of Zoom's recent IPO, it's worth understanding why collaboration tools are important and the real impact they are having on both users and the market. OUR “In Case You Missed It” FAST FIVE > Support for Facebook's new Libra cryptocurrency looks, well, pretty good from a transactional perspective. > Huawei delay's the launch of its Mate Foldable, in what may be a complete reworking of its product and OS strategy. > 5G myths, like flat earth beliefs, are upon us conspiracy theories abound and they're not just believed but they're starting to impact political/policy discussions. > Microsoft and Oracle partner to deliver interoperability between Azure and the Oracle Cloud. > Dassault Systèmes, the French “3D Experience” company, has acquired US-based Medidata, exchanging $5.8b for a solid footprint in the SaaS-based medical software market. OUR TECH BITES WINNER: Deep Fakes are back, and the tech giants aren't quite sure what to do about them, including Facebook which has taken a no-action action regarding the removal of fake, abusive content. OUR CRYSTAL BALL PREDICTION: What does the (short-term) future hold for Slack's upcoming IPO? INFORMATION: This Futurum Podcast features Daniel Newman (@danielnewmanUV), Fred McClimans (@fredmcclimans) and Olivier Blanchard (@OABlanchard). If you haven't already, please subscribe to our show on iTunes or SoundCloud. For inquiries or more information on the show, email the team at podcast@futurumresearch.com or follow @FuturumPodcast on Twitter. To learn more about Futurum Research please visit www.futurumresearch.com. DISCLOSURE: Futurum Research is a research and analysis provider, not an investment advisor. The Futurum Tech Podcast (and all related written notes and materials) is a newsletter/podcast intended for entertainment and informational purposes only. Futurum Research does not provide personalized investment advice and no investment advice is offered or implied by this podcast.

Congratulations to Medidata for winning this award. Medidata is a company that is well known in the clinical research sphere because of their solutions for entering data and clinical trial management systems. Ever since Risk Based Monitoring has become in the forefront since the ICH GCP R2 guidelines were implemented in the end of 2016, Medidata has been working on their solution to better implement Risk Based Monitoring. They have won this award for the past three years and we can definitely see why. Don't forget to Subscribe for new content! Email: eliteclinicalgroup@gmail.com Podcast: https://anchor.fm/clinical-research-p... Steemit: https://steemit.com/@ecrgmedia Watch: » Industry News: https://goo.gl/fNXpQ5 » All Videos: https://goo.gl/87XEFW » Interview Recaps: https://goo.gl/wJsk6W » Glassdoor Reviews: https://goo.gl/AbQzqe --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/clinical-research-podcast/message Support this podcast: https://anchor.fm/clinical-research-podcast/support

http://www.TheClinicalTrialsGuru.comSite Owner Academy: http://www.theclinicaltrialsguru.com/site-owner-academy/My CRO: http://www.DSCScro.comMy CRA Academy: http://www.TheCRAacademy.comMy Research News Site: http://www.TheClinicalScoop.comCall/Text: (949) 415-6256Follow Me On:SnapChat: username is dansferaInstagram: https://instagram.com/dansferaTwitter: https://twitter.com/TheRealDanSferaFacebook: https://www.facebook.com/dansferaLinkedIn: https://www.linkedin.com/profile/view...My iTunes Podcast: https://itunes.apple.com/us/podcast/random-musings-from-the-clinical-trials-guru/id1245751329My Stitcher Podcast: http://www.stitcher.com/podcast/dan-s...Google Play Podcast: https://playmusic.app.goo.gl/?ibi=com.google.PlayMusic&isi=691797987&ius=googleplaymusic&link=https://play.google.com/music/m/Ikoltbj2pxcbscwwajoixxdhix4?t%3DRandom_Musings_From_The_Clinical_Trials_Guru%26pcampaignid%3DMKT-na-all-co-pr-mu-pod-16

Ramin Sayar. He’s currently the president and CEO of Sumo Logic, an industry-leading SaaS-based company backed by some great VCs and he has an impressive list of customers and partners. Previously, he was the senior VP and GM at VMware, where he developed the product and business strategy and led the fastest growing aspect of that business. Previously, he had multiple executive roles with leading companies such as HP Software, Mercury Software, Tibco software, iPlanet Software, AOL and Netscape. Famous Five: Favorite Book? – Good to Great What CEO do you follow? – Tom Reilly Favorite online tool? — Twitter and LinkedIn How many hours of sleep do you get?— Around 6-7 If you could let your 20-year old self, know one thing, what would it be? – Ramin would tell himself that the flow and steady path will pay off in the long run   Time Stamped Show Notes: 02:22 – Nathan introduces Ramin to the show 03:32 – Sumo Logic helps customers build, run and secure modern apps in a simple and easy to consume service of profitability 03:57 – Sumo Logic is a SaaS business 04:04 – Priced and licensed depending on the data ingested and the duration of retention 04:25 – Average RPU varies 05:35 – Sumo Logic has a mass of service for their customers 05:45 – Sumo Logic has some free services 06:18 – Customers’ buying pattern is consistent 06:43 – $15K-150K is the average contract price 07:34 – Sumo Logic has over 1300 paying customers 07:42 – 51% is enterprise and the other half is midmarket and SMBs 08:22 – Sumo Logic was capitalized through 5 rounds 08:34 – Total amount raised is over $160M 08:52 – Nathan had Tim Draper at Episode 129 from DFJ which Ramin mentioned 09:14 – Sumo Logic is 7 years old 09:33 – Sumo Logic’s founding roots came from the security roles 09:38 – Not all users have access to data being generated 09:48 – The founders believed that there should be a simpler way for more users to access data 10:32 – The team initially felt that there was a competitive advantage in technology and an innovative way to deliver data analytics as a service 11:03 – Sumo Logic currently has 30K users 11:17 – Their vision was to democratize machine data 11:50 – Visa has been with Sumo Logic for a few years now 12:04 – Visa started with their fraud detection cases 12:23 – A few years ago, Visa launched a service with Apple 12:32 – Visa uses Sumo Logic for business insights such as activation and patterns regarding how users use multiple credit card applications 12:58 – Medidata is trying to disrupt the pharmaceutical industry in the clinical trial process 13:23 – Medidata used Sumo and decided they’re going to transfer to the public cloud infrastructure service 13:42 – Medidata is an example of a different, non-tech company using the technology that Sumo Logic provides 14:10 – Sumo Logic assimilates, collects, ingests and analyzes different sources of data 14:25 – Sumo Logic then purposely tailors the analysis through their machine learning algorithms to address 3 distinct use cases 14:52 – Sumo Logic helps in continuous development 15:07 – Sumo Logic provides one single platform that analyses information and puts it into context so that developers and other teams can get the 360 degree, holistic view of the information 15:39 – Sumo Logic analyses a lot of patterns 16:34 – Ramin joined Sumo Logic 2 years ago 17:06 – In choosing a CEO, it comes with understanding the core values and culture of the company and how they relate to what the founders want 17:20 – If there are odds, make sure to address them 17:25 – Second is to make sure that there’s an alignment syndicate in founding members in terms of what the outcomes would be 17:36 – Some CEOs are brought in to scale the company and in other cases, they are brought in to turn over the team or change the company’s direction 18:10 – One of the 2-3 founders of Sumo Logic is still on the team 19:00 – Average ARR 19:30 – “We don’t try to make consumers consume what they can’t initially” 19:40 – SaaS companies often have to prove their value and constantly fight to earn the business 19:56 – More customers are now signing multimillion year deals with Sumo Logic 20:09 – The customers are seeing Sumo Logic’s value 21:12 – The enterprise segment for Sumo Logic is broad 21:26 – When Ramin first came to Sumo Logic, the focus was security 21:43 – Ramin realized that most of their customers are development ops, tech ops and liability engineers, so they pivoted a bit 22:25 – For a SaaS company, the LTV to CAC that modern investors look for are the payback period and the magic number has to be 3.0 and more 22:50 – The other metrics that Sumo Logic tracks 24:09 – Sumo Logic’s payback period is between the 1-2 year mark 25:13 – The enterprise, midmarket and SMBs have different payback periods 25:39 – Team size is 250 27:33 – The Famous Five   3 Key Points: Create guidelines when it comes to looking for your CEOs—they should align with the company’s cultures, beliefs, and goals. SaaS companies often have to prove their value and are constantly fighting to earn business. Users’ access to data can be very limited and complicated; however, simpler and more innovative ways are being discovered as technology continues to advance.   Resources Mentioned: The Top Inbox – The site Nathan uses to schedule emails to be sent later, set reminders in inbox, track opens, and follow-up with email sequences Organifi – The juice was Nathan’s life saver during his trip in Southeast Asia Klipfolio – Track your business performance across all departments for FREE Acuity Scheduling – Nathan uses Acuity to schedule his podcast interviews and appointments Host Gator– The site Nathan uses to buy his domain names and hosting for the cheapest price possible Audible– Nathan uses Audible when he’s driving from Austin to San Antonio (1.5-hour drive) to listen to audio books Freshbooks – Nathan doesn’t waste time so he uses Freshbooks to send out invoices and collect his money. Get your free month NOW Show Notes provided by Mallard Creatives

The gap between the promise and practice of technology has been especially vivid in the area of pharmaceutical clinical trials, where even switching from paper to electronic data capture has proved too radical for some sponsors. Today’s guest, Kara Dennis, who is the managing director of digital health at Medidata, seeks to change all this […]

Edward Seguine is the CEO of Clinical Ink, a pioneer in the development of electronic source record solutions for clinical research.  Prior to Clinical Ink, Mr. Seguine was the General Manager of Medidata's Trial Planning product suite after serving as the CEO of Fast Track Systems before that company was acquired by Medidata.Mr. Seguine began his pharma career at Eli Lilly where he helped establish Lilly's venture capital groups e.Lilly and Lilly Bioventures. Mr. Seguine has participated as an active board member and advisor for numerous start-up companies as well as CDISC.  In addition, he has actively collaborated with leading academic institutions (Tufts CSDD, MIT, Duke) to develop, publish and present research into novel approaches to improving clinical development.  Ed earned a BS in Finance from Brigham Young University, an MBA from Indiana University, and spent several years early in his career as the VP Finance of a start-up defense technology company. In this interview, Ed discusses the $7-10B industry of monitoring research sites for clinical trials, as well as the broader context and process of this dynamic and critical space including Meaningful Use.

Thought Leaders: Jessica Dolfi, MS, Senior Business Consultant, Medidata Solutions Worldwide and Kelly Willenberg, MBA, BSN, CHRC, CHC, Kelly Willenberg, LLCIn this episode, we discuss standard of care in clinical trials, challenges for sites and sponsors, and how standard of care issues affect day-to-day work in trials.For more information about Medidata Solutions Worldwide, visit www.mdsol.com.Play Podcast.For more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.